通讯（含共同）作者论文：
1. X. Nie, Y. Liu, X. Yao, Q. Zhang, Y. Huang, K. Mattursun, Y. Feng, T. Liang, L. Yang, X. Gao, Erythrocyte-anti-PD1 conjugates in persons with advanced solid tumors resistant to anti-PD1/PDL1: preclinical characterization and results of a phase 1 trial. Nat Cancer, (2026).
2. Z. J. Cao, J. You, Y. M. Fan, J. Y. Yang, J. Sun, X. Ma, J. Zhang, Z. Li, X. Wang, Y. X. Feng, Noncanonical UPR factor CREB3L2 drives immune evasion of triple-negative breast cancer through Hedgehog pathway modulation in T cells. Sci Adv 11, eads5434 (2025).
3. L. X. Yang, C. Qi, S. Lu, X. S. Ye, P. Merikhian, D. Y. Zhang, T. Yao, J. S. Zhao, Y. Wu, Y. Jia, B. Shan, J. Chen, X. Mou, J. You, W. Li, Y. X. Feng, Alleviation of liver fibrosis by inhibiting a non-canonical ATF4-regulated enhancer program in hepatic stellate cells. Nat Commun 16, 524 (2025).
4. S. Lu, R. Zhao, Y. Han, S. Shao, Y. Ji, J. Zhang, H. Pan, J. Sun, Y. Feng, Identification of PFKFB3 as a key factor in the development of colorectal cancer and immunotherapy resistance. Clin Exp Med 24, 219 (2024).
5. T. Wang, L. Feng, Z. Shi, L. Yang, X. Yu, J. Wu, J. Sun, J. Zhang, Y. Feng, W. Wang, A negative feedback loop between KLF9 and the EMT program dictates metastasis of hepatocellular carcinoma. J Cell Mol Med 27, 2372-2384 (2023).
6. J. S. Zhao, S. Shi, H. Y. Qu, Z. Keckesova, Z. J. Cao, L. X. Yang, X. Yu, L. Feng, Z. Shi, J. Krakowiak, R. Y. Mao, Y. T. Shen, Y. M. Fan, T. M. Fu, C. Ye, D. Xu, X. Gao, J. You, W. Li, T. Liang, Z. Lu, Y. X. Feng, Glutamine synthetase licenses APC/C-mediated mitotic progression to drive cell growth. Nat Metab 4, 239-253 (2022).
7. S. Lu, L. X. Yang, Z. J. Cao, J. S. Zhao, J. You, Y. X. Feng, Transcriptional Control of Metastasis by Integrated Stress Response Signaling. Front Oncol 11, 770843 (2021).
8. M. Feng, J. Q. Jin, L. Xia, T. Xiao, S. Mei, X. Wang, X. Huang, J. Chen, M. Liu, C. Chen, S. Rafi, A. X. Zhu, Y. X. Feng, D. Zhu, Pharmacological inhibition of beta-catenin/BCL9 interaction overcomes resistance to immune checkpoint blockades by modulating T(reg) cells. Sci Adv 5, eaau5240 (2019).
受邀评述和综述:
1. B. N. Sheikh, Y. X. Feng, Career pathways, part 12. Nat Metab 5, 1642-1645 (2023).
2. S. Lu, Q. Zhou, R. Zhao, L. Xie, W. M. Cao, Y. X. Feng, Unraveling UPR-mediated intercellular crosstalk: Implications for immunotherapy resistance mechanisms. Cancer Lett 617, 217613 (2025).
3. L. Chen, X. Ye, L. Yang, J. Zhao, J. You, Y. Feng, Linking fatty liver diseases to hepatocellular carcinoma by hepatic stellate cells. J Natl Cancer Cent 4, 25-35 (2024).
· 第一（含共同）作者论文：
1. Y. X. Feng, D. X. Jin, E. S. Sokol, F. Reinhardt, D. H. Miller, P. B. Gupta, Cancer-specific PERK signaling drives invasion and metastasis through CREB3L1. Nat Commun 8, 1079 (2017).
2. E. S. Sokol, Y. X. Feng, D. X. Jin, M. D. Tizabi, D. H. Miller, M. A. Cohen, S. Sanduja, F. Reinhardt, J. Pandey, D. A. Superville, R. Jaenisch, P. B. Gupta, SMARCE1 is required for the invasive progression of in situ cancers. Proc Natl Acad Sci U S A 114, 4153-4158 (2017).
3. Y. X. Feng, E. S. Sokol, C. A. Del Vecchio, S. Sanduja, J. H. Claessen, T. A. Proia, D. X. Jin, F. Reinhardt, H. L. Ploegh, Q. Wang, P. B. Gupta, Epithelial-to-mesenchymal transition activates PERK-eIF2alpha and sensitizes cells to endoplasmic reticulum stress. Cancer Discov 4, 702-715 (2014).
4. Y. X. Feng, T. Wang, Y. Z. Deng, P. Yang, J. J. Li, D. X. Guan, F. Yao, Y. Q. Zhu, Y. Qin, H. Wang, N. Li, M. C. Wu, H. Y. Wang, X. F. Wang, S. Q. Cheng, D. Xie, Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model. Hepatology 53, 483-492 (2011).
5. Y. X. Feng, J. S. Zhao, J. J. Li, T. Wang, S. Q. Cheng, Y. Yuan, F. Wang, X. F. Wang, D. Xie, Liver cancer: EphrinA2 promotes tumorigenicity through Rac1/Akt/NF-kappaB signaling pathway. Hepatology 51, 535-544 (2010).
